Citations

Clear

117 citation(s) found for "Carson, C C".

Abstract CT194: ETCTN 10388: a first in human phase I trial of triapine and lutetium Lu 177 DOTATATE in well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Chauhan, Aman, Weiss, Heidi L. , Jayswal, Rani, Khouli, Riham El , Khurana, Aman , Beumer, J. J., Mulcahy, Mary F. , Jacene, Heather A. , Kohn, Elise C. , Chow, Zeta, Evers, Mark B., Kunos, Charles A., Anthony, Lowell , Arnold, Susanne M. , Kolesar, Jill , Carson, William E. , Yan, Donglin , Beumer, Jan Hendrik , Soares, Heloisa P. , Hálfdánarson, Þorvarður R. , Li, Daneng , Ivy, S. Percy , Wright, John, Rubinstein, Larry , Rychahou, Piotr G. , Konda, Bhavana

Mayo Clinic

Cancer Research | April 14, 2023 | Volume: 83 | Issue: 8_Supplement | Pages: CT194-CT194

10.1158/1538-7445.am2023-ct194 Get It

Abstract Background: Radiation is a potent inducer of DNA double-strand breaks, and ribonucleotide reductase (RNR) is the rate-limiting enzyme in the synthesis and repair of DNA, making RNR-targeted therapy a rationale therapeutic strategy for radiosensitization. ETCTN 10388 (NCT04234568) evaluated safety and efficacy of the combination of lutetium 177 DOTATATE, a beta-emitting radionuclide in combination with triapine, a ribonucleotide reductase (RNR) inhibitor. Method: This study was a multicenter phase 1 dose escalation trial [using the Bayesian optimal interval design (BOIN)] of triapine in combination with fixed dose lutetium Lu 177 DOTATATE for well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumor (GEP-NETs) after the failure of at least one line of prior systemic cancer treatment with an expansion cohort at the recommended phase 2 dose (RP2D). Oral triapine (100mg, 150mg, 200mg) was administered once daily on days 1-14 and Lu-177 DOTATATE [200 mCi] intravenously on day 1 of every 56-day cycle. A total of 4 cycles were administered. Response and adverse effects were assessed per RECIST and CTCAE 5.0, respectively. Exploratory correlative studies included tumor somatic and germline mutation testing, RNA sequencing, pharmacokinetics, deoxynucleosides and circulating cell free DNA analysis. Primary endpoints were safety and RP2D. Results: Overall, 31 patients were enrolled between 6 sites, 15 in the dose escalation phase and 16 in the dose expansion phase. Adverse events (AE) were assessed in all 31 patients per CTCAE 5.0. One DLT in dose level 1, seven DLTs in dose level 2, and one grade 5 DLT in dose level 3 were observed. The RP2D of the combination is triapine 150 mg QD (dose level 2) on days 1-14 in combination with Lu-177 DOTATATE on day 1 of every 56-day cycle. Detailed safety and adverse event data will be presented at the meeting. There were 28 patients evaluable for efficacy, of which 6 (21%) achieved a partial response. At 12 months, 6 patients had progressed, while 22 (86%) remained progression free. Median PFS has not been reached. PK data were available for 12 patients enrolled in the dose escalation cohort. The geometric mean (SD) AUC0-inf was 1159 (1.22) µg/L•h for the 100mg dose level and 1862 (1.76) µg/L•h for the 150 mg dose level, suggesting that exposure increased with dose, and inter-patient variability was as expected for an oral agent. Conclusion: The combination of triapine and Lu-177 DOTATATE was safe with preliminary efficacy signals, which will be further evaluated in ETCTN 10558, a randomized phase 2 study that is comparing the effectiveness of triapine and Lu-177 DOTATATE to Lu-177 DOTATATE alone. Citation Format: Aman Chauhan, Susanne Arnold, Jill Kolesar, William Carson, Heidi Weiss, Rani Jayswal, Donglin Yan, Riham El Khouli, Aman Khurana, Jan Beumer, Heloisa Soares, Mary Mulcahy, Thorvardur Halfdanarson, Daneng Li, Heather Jacene, Percy Ivy, Elise Kohn, John Wright, Larry Rubinstein, Zeta Chow, Piotr Rychahou, Mark B. Evers, Charles Kunos, Lowell Anthony, Bhavana Konda. ETCTN 10388: a first in human phase I trial of triapine and lutetium Lu 177 DOTATATE in well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr CT194.
Pharmacokinetics and RP2D analysis from ETCTN 10388: A phase I trial of triapine and lutetium Lu-177 dotatate in well-differentiated somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Chauhan, Aman, Christner, Susan M., Kunos, Charles A., Khurana, Aman , Khouli, Riham El , Weiss, Heidi, Evers, Mark B., Kohn, Elise C. , Kolesar, Jill , Anthony, Lowell , Beumer, Jan Hendrik , Weiss, Heidi, Yan, Donglin , Soares, Heloisa P. , Hálfdánarson, Þorvarður R. , Li, Daneng , Carson, William E. , Ivy, S. Percy , Rubinstein, Larry , Arnold, Susanne M. , Konda, Bhavana

Mayo Clinic

Journal of Clinical Oncology | February 23, 2023 | Volume: 41 | Issue: 4_suppl | Pages: 648-648

10.1200/jco.2023.41.4_suppl.648 Get It

648 Background: Radiation is a potent inducer of DNA double-strand breaks, and ribonucleotide reductase (RNR) is the rate-limiting enzyme for conversion of ribonucleoside diphosphate to deoxyribonucleotide diphosphate, and thus repair of DNA in this setting. ETCTN 10388 evaluated safety of combination Lu-177 DOTATATE, a beta-emitting radionuclide in combination with triapine, a ribonucleotide reductase (RNR) inhibitor. Methods: This investigator initiated, NCI sponsored, multicenter phase 1 trial, enrolled a total of 31 patients in the dose escalation [using the Bayesian optimal interval design (BOIN)] and dose expansion cohorts. Oral triapine was administered on days 1-14 and Lu-177 DOTATATE [200 mCi] intravenously on day 1 of every 56-day cycle. A total of 4 cycles were administered. All enrolled patients had blood samples collected for triapine pharmacokinetic (PK) analysis in EDTA tubes prior to and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8 h after oral administration during cycle 1. Results: Five patients were enrolled in triapine Dose Level 1 (100 mg/day), twenty-five to dose level two (150 mg/day), and one patient to dose level three (200 mg/day). PK data were available for 12 patients enrolled in the dose escalation cohort. The geometric mean (SD) AUC0-inf was 1159 (1.22) µg/L•h for the 100mg dose level and 1862 (1.76) µg/L•h for the 150 mg dose level, suggesting that exposure increased with dose, and inter-patient variability was as expected for an oral agent. Triapine PK parameter values observed in this trial, were comparable to previous reports that used a previous formulation [ 1 ]. While exposure was similar, variability appeared smaller with the current oral formulation. Adverse events (AE) were assessed in all 31 patients per CTCAE 5.0. A total of one DLT in dose level 1, seven DLTs (Transient cytopenia; primarily neutropenia and rarely thrombocytopenia) in dose level 2, and one grade 5 DLT (Death probably from progressive cancer and carcinoid heart disease but possibly from trial drugs) in dose level 3 were observed. Detailed AE profile will be presented at the meeting. Conclusions: The RP2D of triapine is 150 mg QD on days 1-14 in combination with Lu-177 DOTATATE on day 1 of every 56-day cycle. Clinical trial information: 04234568 .
Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study
Usmani, Saad Z. , Plesner, Torben , Hulin, Cyrille , Goldschmidt, Hartmut , Venner, Christopher P. , Tiab, Mourad, Macro, Margaret , Leleu, Xavier , Pei, Huiling , Krevvata, Maria, Carson, Robin, Borgsten, Fredrik, Kumar, Shaji , Usmani, Saad , Moreau, Philippe , Facon, Thierry T.F. , Bahlis, Nizar Jacques , Raje, Noopur , Orlowski, Robert Z. , Basu, Supratik , Nahi, Hareth , Quach, Hang , O’Dwyer, Michael , Perrot, Aurore , Weisel, Katja C , Frenzel, Laurent

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 7297-7300

10.1182/blood-2022-163494 Get It

Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis
Kumar, Shaji , Plesner, Torben , Hulin, Cyrille , Venner, Christopher P. , Tiab, Mourad, Macro, Margaret , Leleu, Xavier , Pei, Huiling , Carson, Robin, Borgsten, Fredrik, Goldschmidt, Hartmut , Facon, Thierry T.F. , Weisel, Katja C , Usmani, Saad Z. , Moreau, Philippe , Orlowski, Robert Z. , Bahlis, Nizar Jacques , Basu, Supratik , Nahi, Hareth , Quach, Hang , O’Dwyer, Michael , Perrot, Aurore , Raje, Noopur , Frenzel, Laurent

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 10133-10136

10.1182/blood-2022-163555 Get It

Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA Trial
Plesner, Torben , Usmani, Saad Z. , Kumar, Shaji , Hulin, Cyrille , Roussel, Murielle , Delforge, Michel, Karlin, Lionel , Arnulf, Bertrand , Pei, Huiling , Gupta, Niodita, Kaila, Shuchita, Matt, Kathryn, Gries, Katharine S. , Carson, Robin, Borgsten, Fredrik, Usmani, Saad , Roussel, Murielle , Perrot, Aurore , Facon, Thierry T.F. , Bahlis, Nizar Jacques , Orlowski, Robert Z. , Nahi, Hareth , Mollee, Peter , Ramasamy, Karthik , Jaccard, Arnaud , Chari, Ajai , Weisel, Katja C

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 1142-1145

10.1182/blood-2022-165524 Get It

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study
Kumar, Shaji , Plesner, Torben , Hulin, Cyrille , Goldschmidt, Hartmut , Venner, Christopher P. , Tiab, Mourad, Macro, Margaret , Leleu, Xavier , Pei, Huiling , Krevvata, Maria, Carson, Robin, Borgsten, Fredrik, Moreau, Philippe , Bahlis, Nizar Jacques , Facon, Thierry T.F. , Orlowski, Robert Z. , Basu, Supratik , Nahi, Hareth , Quach, Hang , O’Dwyer, Michael , Perrot, Aurore , Weisel, Katja C , Raje, Noopur , Frenzel, Laurent , Usmani, Saad Z.

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 10150-10153

10.1182/blood-2022-163335 Get It

Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
Sonneveld, Pieter , Chanan‐Khan, Asher , Nooka, Ajay K. , Beksaç, Meral , Hungria, Vânia , Munder, Markus , Mateos, María‐Victoria , Ahmadi, Tahamtan , Qin, Xiang , Mayo, Wendy Garvin, Gai, Xue , Carey, Jodi, Carson, Robin, Spencer, Andrew , Nooka, Ajay K , Masszi, Tamas , Beksac, Meral , Hungria, Vania , Munder, Markus , Mateos, María-Victoria , Mark, Tomer M , Levin, Mark-David , Gai, Xue , Spencer, Andrew , Weisel, Katja C , Masszi, Tamás , Špıčka, Ivan

Mayo Clinic

Journal of Clinical Oncology | November 22, 2022 | Volume: 41 | Issue: 8 | Pages: 1600-1609

10.1200/jco.21.02734 | PMID 36413710 Get It

PURPOSE At the primary analysis of CASTOR (median follow-up, 7.4 months), daratumumab plus bortezomib and dexamethasone (D-Vd) significantly prolonged progression-free survival versus bortezomib and dexamethasone (Vd) alone in relapsed or refractory multiple myeloma (RRMM). We report updated efficacy and safety results at the final analysis for overall survival (OS). METHODS CASTOR was a multicenter, randomized, open-label, phase III study during which eligible patients with ≥ 1 line of prior therapy were randomly assigned to Vd (up to eight cycles) with or without daratumumab (until disease progression). After positive primary analysis and protocol amendment, patients receiving Vd were offered daratumumab monotherapy after disease progression. RESULTS At a median (range) follow-up of 72.6 months (0.0-79.8), significant OS benefit was observed with D-Vd (hazard ratio, 0.74; 95% CI, 0.59 to 0.92; P = .0075). Median OS was 49.6 months with D-Vd versus 38.5 months with Vd. Prespecified subgroup analyses demonstrated an OS advantage with D-Vd versus Vd for most subgroups, including patients age ≥ 65 years and patients with one or two prior lines of therapy, International Staging System stage III disease, high-risk cytogenetic abnormalities, and prior bortezomib treatment. The most common (≥ 10%) grade 3/4 treatment-emergent adverse events with D-Vd versus Vd were thrombocytopenia (46.1% v 32.9%), anemia (16.0% v 16.0%), neutropenia (13.6% v 4.6%), lymphopenia (10.3% v 2.5%), and pneumonia (10.7% v 10.1%). CONCLUSION D-Vd significantly prolonged OS in patients with RRMM, with the greatest OS benefit observed in patients with one prior line of therapy. To our knowledge, our results, together with the OS benefit observed with daratumumab plus lenalidomide and dexamethasone in the phase III POLLUX study, demonstrate for the first time an OS benefit with daratumumab-containing regimens in RRMM (ClinicalTrials.gov identifier: NCT02136134 [CASTOR]).
A noncoding single-nucleotide polymorphism at 8q24 drives IDH1 -mutant glioma formation
Yanchus, Connor , Drucker, Kristen , Kollmeyer, Thomas M. , Tsai, Ricky , Winick‐Ng, Warren , Liang, Minggao , Malik, Ahmad , Pawling, Judy , Lorenzo, Silvana B. De, Ali, Asma, Decker, Paul A. , Kosel, Matt, Panda, Arijit , Al‐Zahrani, Khalid N. , Jiang, Lingyan , Browning, Jared , Lowden, Christopher , Hernández, J. Javier , Gosio, Jessica , Loganathan, Sampath K. , Berman, Jacob M. , Trcka, Daniel , Michealraj, Kulandaimanuvel Antony , Fortin, Jérôme, Carson, Brittany B. , Hollingsworth, Ethan W. , Jacinto, Sandra , Mazrooei, Parisa, Zhou, Lily , Elia, Andrew , Lupien, Mathieu , Murphy, Daniel J. , Wang, Liguo , Abyzov, Alexej , Dennis, James W. , Maass, Philipp G. , Wrensch, Margaret , Mak, Tak W. , Visel, Axel , Wrana, Jeffrey L. , Zadeh, Gelareh , Eckel‐Passow, Jeanette E. , Attisano, Liliana , Pombo, Ana , Kvon, Evgeny Z. , Jenkins, Robert B. , Schramek, Daniel , Drucker, Kristen L , De Lorenzo, Silvana B, Kosel, Matt L, Browning, Jared W L , Lowden, Chris , Hernandez, J Javier , Ahmed, Musaddeque , Loganathan, Sampath Kumar , Berman, Jacob , Trcka, Daniel , Hollingsworth, Ethan W , Elia, Andrew , Lupien, Mathieu , He, Housheng Hansen , Wang, Liguo , Abyzov, Alexej , Dennis, James W , Maass, Philipp G , Wilson, Michael D , Wrensch, Margaret , Mak, Tak , Pennacchio, Len A , Dickel, Diane E , Visel, Axel , Wrana, Jeffrey , Dirks, Peter , Eckel-Passow, Jeanette E , Attisano, Liliana , Pombo, Ana , Ida, Cristiane M , Kvon, Evgeny Z , Jenkins, RB , Schramek, Daniel , Kollmeyer, Thomas , Murphy, Daniel J , Decker, Paul A. , Kosel, Matthew , Geuenich, Michael J. , Ahmed, Musaddeque , He, Housheng Hansen , Campbell, Kieran R. , Wilson, Michael D. , Lachance, Daniel Honore , Wiencke, John K. , Taylor, Michael D. , Ida, Cristiane M.

Mayo Clinic

Science | October 6, 2022 | Volume: 378 | Issue: 6615 | Pages: 68-78

10.1126/science.abj2890 | PMID 36201590 Get It

Establishing causal links between inherited polymorphisms and cancer risk is challenging. Here, we focus on the single-nucleotide polymorphism rs55705857, which confers a sixfold greater risk of isocitrate dehydrogenase ( IDH) –mutant low-grade glioma (LGG). We reveal that rs55705857 itself is the causal variant and is associated with molecular pathways that drive LGG. Mechanistically, we show that rs55705857 resides within a brain-specific enhancer, where the risk allele disrupts OCT2/4 binding, allowing increased interaction with the Myc promoter and increased Myc expression. Mutating the orthologous mouse rs55705857 locus accelerated tumor development in an Idh1 R132H -driven LGG mouse model from 472 to 172 days and increased penetrance from 30% to 75%. Our work reveals mechanisms of the heritable predisposition to lethal glioma in ~40% of LGG patients.
Gastric dysfunction in patients with chronic nausea and vomiting syndromes defined by a noninvasive gastric mapping device
Gharibans, Armen A. , Calder, Stefan , Varghese, Chris , Waite, Stephen , Schamberg, Gabriel , Daker, Charlotte , Du, Peng , Carson, D A, Woodhead, Jonathan S. T., Farrugia, Gianrico , Windsor, John A. , Andrews, Christopher N. , O’Grady, Greg, Alighaleh, Saeed , Carson, Daniel , Farrugia, Gianrico , O'Grady, Gregory , Varghese, Chris , Gharibans, Armen A , Andrews, Christopher N , Schamberg, Gabriel , Daker, Charlotte

Mayo Clinic

Science Translational Medicine | September 21, 2022 | Volume: 14 | Issue: 663 | Pages: No page available

10.1126/scitranslmed.abq3544 | PMID 36130019 Get It

Chronic nausea and vomiting syndromes (NVSs) are prevalent and debilitating disorders. Putative mechanisms include gastric neuromuscular disease and dysregulation of brain-gut interaction, but clinical tests for objectively defining gastric motor function are lacking. A medical device enabling noninvasive body surface gastric mapping (BSGM) was developed and applied to evaluate NVS pathophysiology. BSGM was performed in 43 patients with NVS and 43 matched controls using Gastric Alimetry (Alimetry), a conformable high-resolution array (8 × 8 electrodes; 20-mm interelectrode spacing), wearable reader, and validated symptom-logging app. Continuous measurement encompassed a fasting baseline (30 minutes), 482-kilocalorie meal, and 4-hour postprandial recording, followed by spectral and spatial biomarker analyses. Meal responses were impaired in NVS, with reduced amplitudes compared to controls (median, 23.3 microvolts versus 38.0 microvolts, P < 0.001), impaired fed-fasting power ratios (1.1 versus 1.6, P = 0.02), and disorganized slow waves (spatial frequency stability, 13.6 versus 49.5; P < 0.001). Two distinct NVS subgroups were evident with indistinguishable symptoms (all P > 0.05). Most patients (62%) had normal BSGM studies with increased psychological comorbidities (43.5% versus 7.7%; P = 0.03) and anxiety scores (median, 16.5 versus 13.0; P = 0.035). A smaller subgroup (31%) had markedly abnormal BSGM, with biomarkers correlating with symptoms (nausea, pain, excessive fullness, early satiety, and bloating; all r > 0.35, P < 0.05). Patients with NVS share overlapping symptoms but comprise distinct underlying phenotypes as revealed by a BSGM device. These phenotypes correlate with symptoms, which should inform clinical management and therapeutic trial design.